Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 7NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 513Breast Neoplasms, Male 79Ovarian Neoplasms 54Triple Negative Breast Neoplasms 46Lung Neoplasms 43Colonic Neoplasms 41Prostatic Neoplasms 38Neoplasms 38Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 33Melanoma 31Pancreatic Neoplasms 29Colorectal Neoplasms 28Stomach Neoplasms 24Carcinoma, Ovarian Epithelial 24Endometrial Neoplasms 23Carcinoma, Renal Cell 23Inflammatory Breast Neoplasms 21Brain Neoplasms 20Carcinoma, Intraductal, Noninfiltrating 19Breast Carcinoma In Situ 19Rectal Neoplasms 18Urinary Bladder Neoplasms 17Lymphoma, Non-Hodgkin 17Lymphoma, T-Cell, Cutaneous 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Neoplasms 16Uterine Cervical Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma 15

Interventions

Pyridoxine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hand-Foot Syndrome × Breast × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡